Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.
The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.
Immunocore Holdings plc reported that director Kristine Peterson received a stock option grant covering 27,492 ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036. The award vests at the earlier of May 27, 2027 or the day immediately prior to the company’s next annual general meeting, contingent on her continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Immunocore Holdings plc director William Pao received a new stock option grant. The award covers 27,492 options to buy Ordinary Shares at an exercise price of $28.52 per share, expiring on May 26, 2036.
The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting, as long as Pao remains in continuous service through the vesting date. Following this grant, he holds 27,492 share options directly.
Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares. The options carry an exercise price of $28.52 per share and expire on May 26, 2036, providing long-term equity-based compensation.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, as long as Kaul remains in continuous service until that vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036, according to the Form 4.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service through the vesting date. After this grant, the filing shows 27,492 derivative securities held directly.
Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options. Each option gives the right to buy one ordinary share at an exercise price of $28.52 and expires on May 26, 2036. According to the terms, the options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service until that vesting date. Following this award, he holds 27,492 derivative securities linked to ordinary shares.
Immunocore Holdings plc reported the results of its 2026 Annual General Meeting of Shareholders. All ten resolutions proposed at the meeting were approved on a poll.
Shareholders re-appointed directors Siddharth Kaul, William Pao, M.D., Ph.D., and Kristine Peterson. They also approved, on an advisory basis, the compensation of named executive officers and the directors’ remuneration report for the year ended December 31, 2025.
Deloitte LLP was ratified as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026 and re-appointed as U.K. statutory auditors, with the audit committee authorized to set their remuneration. Shareholders received and adopted the 2025 U.K. statutory annual accounts and reports and authorized the Company to make political donations or incur political expenditure.
Immunocore Holdings Plc reports a proposed sale of 69,271 ADRs by means of a same-day cashless exercise and sale scheduled for 05/26/2026 with cash settlement. The filing lists recent sales by David Berman: 11,832 ADRs on 03/11/2026 for $385,330.11, 25,000 ADRs on 04/08/2026 for $798,510.57, and 65,000 ADRs on 05/21/2026 for $1,894,638.32.
Immunocore Holdings Plc disclosed a proposed sale of 65,000 ADRs via a Same Day Cashless Exercise and Sale scheduled on 05/21/2026 with expected settlement on 05/22/2026. The filing also lists prior sales by David Berman of 11,832 ADRs on 03/11/2026 and 25,000 ADRs on 04/08/2026, with reported gross proceeds of $385,330.11 and $798,510.57, respectively.
Immunocore Holdings plc: Vestal Point Capital, LP and Ryan Wilder report shared beneficial ownership of 2,766,868 ADS, representing 5.5% of the class. The percentage is calculated using 50,695,078 shares outstanding as of January 31, 2026 from the company's Form 10-K. The filing states the ADSs are directly held by the Vestal Point Fund and Account and lists the reporting persons' business address. The statement is signed by Ryan Wilder on behalf of Vestal Point Capital, LLC and individually on May 15, 2026.